Daniel Peterson

Daniel L. Peterson, MD, is a physician in Incline Village, Nevada specializing in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). He was at the epicenter of the 1984 Incline Village chronic fatigue syndrome outbreak and continues to be a leader in treatment and research about ME/CFS, serving on Simmaron Research’s Scientific Advisory Board and the Faculty of Health Sciences and Medicine at Griffith University in Queensland, Australia.

He helped establish the Whittemore Peterson Institute (WPI) which was renamed in 2016 to the Nevada Center for Biomedical Research. He left in 2010 to return to private practice at Sierra Internal Medicine, Incline Village, Nevada.

In 2003, he co-authored the Canadian Consensus Criteria for Myalgic Encephalomyelitis, published as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome:Clinical Working Case Definition, Diagnostic and Treatment Protocols Other authors include: Bruce Carruthers, Anil Kumar Jain, Kenny de Meirleir, Nancy Klimas, A Martin Lerner, Alison Bested, Pierre Flor-Henry, Pradip Joshi, A C Peter Powles, Jeffrey Sherkey, Marjorie van de Sande

Dr. Peterson was the first physician to use Ampligen, an immunomodulator made by Hemispherx Biopharma, in the treatment for ME/CFS, using it on Nancy Kaiser, a very severe patient. He has participated in every Ampligen trial since, up to the AMP-511, open label, cost-recovery trial available today.

Several documentaries about myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have featured Dr. Peterson, including, I Remember Me and Forgotten Plague, and the news feature, Sick and Tired.

Awards

 * 2003, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FM scientist, physician or healthcare worker awarded by IACFS/ME
 * 2007, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by IACFS/ME

Notable Studies

 * 2016, Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome."Abstract: 'Myalgic encephalomyelitis/chronic fatigue syndrome is an unexplained debilitating disorder that is frequently associated with cognitive and motor dysfunction. We analyzed cerebrospinal fluid from 32 cases, 40 subjects with multiple sclerosis and 19 normal subjects frequency-matched for age and sex using a 51-plex cytokine assay. Group-specific differences were found for the majority of analytes with an increase in cases of CCL11 (eotaxin), a chemokine involved in eosinophil recruitment. Network analysis revealed an inverse relationship between interleukin 1 receptor antagonist and colony-stimulating factor 1, colony-stimulating factor 2 and interleukin 17F, without effects on interleukin 1α or interleukin 1β, suggesting a disturbance in interleukin 1 signaling. Our results indicate a markedly disturbed immune signature in the cerebrospinal fluid of cases that is consistent with immune activation in the central nervous system, and a shift toward an allergic or T helper type-2 pattern associated with autoimmunity.'"
 * 2015, Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
 * 2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Abstract
 * 2015, Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Abstract
 * 2015, Distinct plasma immune signatures in ME/CFS are present early in the course of illness  FULL TEXT"'Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an unexplained incapacitating illness that may affect up to 4 million people in the United States alone. There are no validated laboratory tests for diagnosis or management despite global efforts to find biomarkers of disease. We considered the possibility that inability to identify such biomarkers reflected variations in diagnostic criteria and laboratory methods as well as the timing of sample collection during the course of the illness. Accordingly, we leveraged two large, multicenter cohort studies of ME/CFS to assess the relationship of immune signatures with diagnosis, illness duration, and other clinical variables. Controls were frequency-matched on key variables known to affect immune status, including season of sampling and geographic site, in addition to age and sex. We report here distinct alterations in plasma immune signatures early in the course of ME/CFS (n = 52) relative to healthy controls (n = 348) that are not present in subjects with longer duration of illness (n = 246). Analyses based on disease duration revealed that early ME/CFS cases had a prominent activation of both pro- and anti-inflammatory cytokines as well as dissociation of intercytokine regulatory networks. We found a stronger correlation of cytokine alterations with illness duration than with measures of illness severity, suggesting that the immunopathology of ME/CFS is not static. These findings have critical implications for discovery of interventional strategies and early diagnosis of ME/CFS.'"
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome."Abstract: 'A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF-36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated."
 * 1997, Chronic Fatigue Syndrome and Disability
 * 1995, Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen"ABSTRACT: 'Fifteen patients who fit the CDC definition of chronic fatigue syndrome (CFS) and had evidence of severe reduction in performance levels by low Karnofsky performance scores (KPS) of 20-60 were treated with Ampligen. At baseline most patients showed evidence of cerebral dysfunction by neuropsychological testing, were antigen positive by cell culture assay for human herpesvirus-6 (HHV-6), and displayed reduced performance during exercise tolerance testing, as measured by oxygen consumption. These patients represented a subset of CFS patients with especially severe and sustained symptomatology. Following 1248 weeks of Ampligen therapy, sustained improvements were noted in KPS (p < 0.01). Cognitive function improved including IQ and memory. Oxygen uptake and treadmill duration during exercise tolerance testing was also improved after 24 weeks of treatment (p < 0.01). Reduction in HHV-6 expression as measured by the giant cell assay was significant (p < 0.001). Patients continued to show significant improvement late in therapy, taking 8 to 12 weeks as baseline. It was concluded that while receiving Ampligen, the severely afflicted patients studied here derived long-lasting clinical benefit from the Ampligen therapy.'"
 * 1992, A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection

ME/CFS Alert

 * 2013, Episode 50, ME/CFS Alert interview
 * 2012, Episode 26, ME/CFS Alert interview

Invest in ME International ME Conference

 * 2013, Speaker at the 8th Invest in ME International ME Conference on Key Note Speech: The Mainstreaming of ME Research DVD available
 * 2012, Speaker at the 7th Invest in ME International ME Conference on Clinical Research Update 2012 DVD available
 * 2009, Speaker at the 4th Invest in ME International ME Conference on Treatment Regimes for the Most Severe Cases DVD available
 * 2007, Speaker at the 2nd Invest in ME International ME Conference on Biomedical Research DVD available

Other

 * 2015, 2015 De osynliga -Seminarium om ME/CFS, Sweden 19 October
 * 2012, Phoenix Rising - Dr Daniel Peterson (July 12)
 * 2011, Dr. med. Dan Peterson (Simmaron Research) - Diagnose und Behandlung von ME/CFS, Teil 2
 * 2011, Dr. med. Dan Peterson (Simmaron Research) - Diagnose und Behandlung von ME/CFS, Teil 1
 * 2000 Documentary, I Remember Me, directed by Kim A. Snyder
 * 1996, Primetime Live TV Show - Sick and Tired

Online presence

 * Profile
 * PubMed

Learn more

 * Wikipedia - Daniel Peterson (physician)
 * 1990, Chronic Fatigue Syndrome